Innocare Pharma Limited (688428.SH) announced that its self-developed BTK inhibitor, orelabrutinib, has met the primary endpoint in a Phase IIb clinical study for treating systemic lupus erythematosus (SLE). The study has also received approval from China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) to proceed with Phase III registrational clinical trials. The company plans to initiate the trial promptly. Results from the Phase IIb study demonstrated that orelabrutinib exhibited outstanding efficacy, favorable tolerability, and safety in patients treated for 48 weeks.